Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Antyra, Inc. – Product Pipeline Review – H2 2011

VIEWS: 4 PAGES: 20

Antyra, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Antyra, Inc. - Product Pipeline Review - H2 2011” provides data on the Antyra, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Antyra, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Antyra, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Antyra, Inc. - Brief Antyra, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Antyra, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Antyra, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Antyra, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Antyra, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Antyra, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Antyra, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.

More Info
									         Antyra, Inc. – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01425CDB

                                                                                                 Publication Date: OCT 2011




Antyra, Inc. – Product Pipeline Review – H2 2011                                            GMDHC01425CDB / Published OCT 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Antyra, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 3
Antyra, Inc. Snapshot ............................................................................................................................................................................................... 4
      Antyra, Inc. Overview ......................................................................................................................................................................................... 4
      Key Information .................................................................................................................................................................................................. 4
      Key Facts ........................................................................................................................................................................................................... 4
Antyra, Inc. – Research and Development Overview ................................................................................................................................................ 5
      Key Therapeutic Areas ....................................................................................................................................................................................... 5
Antyra, Inc. – Pipeline Review .................................................................................................................................................................................. 7
      Pipeline Products by Stage of Development ....................................................................................................................................................... 7
      Pipeline Products – Monotherapy ...................................................................................................................................................................... 8
Antyra, Inc. – Pipeline Products Glance .................................................................................................................................................................... 9
      Antyra, Inc.–Early Stage Pipeline Products ........................................................................................................................................................ 9
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................. 9
            Discovery Products/Combination Treatment Modalities ..............................................................................................................................10
Antyra, Inc. – Drug Profiles ......................................................................................................................................................................................11
      ANT-429 ...........................................................................................................................................................................................................11
            Product Description ....................................................................................................................................................................................11
            Mechanism of Action...................................................................................................................................................................................11
            R&D Progress .............................................................................................................................................................................................11
      ANT-C7 .............................................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      ANT-G12...........................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action..............................................................................
								
To top